Physician profile
Jennifer Lin
NPI 1184775348
$4,164.53
in general payments reported to CMS, 2019-2025
27 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $188 · 2021: $55.60 · 2022: $357 · 2023: $678 · 2024: $1,173 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $678.72 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $598.71 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $415.03 | 2019-2025 | Tezspire, Airsupra, Farxiga |
| Novo Nordisk INC | $362.13 | 2019-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.80 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $257.91 | 2019-2024 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $195.60 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $173.08 | 2024 | Spravato |
| Amarin Pharma, INC. | $169.39 | 2019-2022 | |
| Pfizer INC. | $154.47 | 2019-2025 | |
| Intuitive Surgical, INC. | $97.24 | 2022 | |
| Abbvie INC. | $83.10 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $78.02 | 2019-2020 | |
| Eisai INC. | $77.71 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $74.14 | 2022-2023 | Austedo Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $73.12 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $67.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.60 | 2019-2023 | Xifaxan, Trulance |
| Stryker Corporation | $55.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.04 | 2019 | |
| Radius Health, INC. | $32.86 | 2019-2020 | |
| Allergan, INC. | $30.30 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $24.94 | 2023 | Gvoke Hypopen |
| Scilex Pharmaceuticals INC. | $24.42 | 2019 | |
| Sumitomo Pharma America, INC. | $24.00 | 2025 | Gemtesa |
| Exact Sciences Corporation | $16.45 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.38 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.